Figure 3.
Figure 3. Consistent targets of HSP90 inhibition across MCL lines. (A) Distribution of proteins that were upregulated (red) or downregulated (green) by log2 fold ≥0.5 following treatment with AUY922 in 1 of 5, 2 of 5, 3 of 5, 4 of 5, and 5 of 5 cell lines. (B) Violin plots of protein fold changes for proteins that were altered by log2 fold ≥0.5 in 1 to 5 cell lines among Mino, JeKo-1, and Maver-1 cell lines following treatment with AUY922 vs DMSO. (C) Heatmap demonstrating protein levels of the most highly regulated proteins by HSP90 inhibition. Proteins were included if they were up or downregulated by log2 fold ≥0.5 in at least 4 of 5 cell lines, demonstrating an abundance of downregulated targets including proteins involved in BCR and JAK/STAT signaling, the nonclassical NF-κB pathway, and DNA repair and cell-cycle control. (D) Immunoblotting of MCL lines for the indicated targets after 48-hour exposure to AUY922 50 nM or vehicle.

Consistent targets of HSP90 inhibition across MCL lines. (A) Distribution of proteins that were upregulated (red) or downregulated (green) by log2 fold ≥0.5 following treatment with AUY922 in 1 of 5, 2 of 5, 3 of 5, 4 of 5, and 5 of 5 cell lines. (B) Violin plots of protein fold changes for proteins that were altered by log2 fold ≥0.5 in 1 to 5 cell lines among Mino, JeKo-1, and Maver-1 cell lines following treatment with AUY922 vs DMSO. (C) Heatmap demonstrating protein levels of the most highly regulated proteins by HSP90 inhibition. Proteins were included if they were up or downregulated by log2 fold ≥0.5 in at least 4 of 5 cell lines, demonstrating an abundance of downregulated targets including proteins involved in BCR and JAK/STAT signaling, the nonclassical NF-κB pathway, and DNA repair and cell-cycle control. (D) Immunoblotting of MCL lines for the indicated targets after 48-hour exposure to AUY922 50 nM or vehicle.

Close Modal

or Create an Account

Close Modal
Close Modal